Skip to main content
Second Circuit· 7/20/2021

Glover v. Bausch & Lomb, Inc.

Citations

  • 6 F.4th 229

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

  • noting that when a party’s claims fail under state law, “the question of federal preemption will be moot”
  • noting that the plaintiffs’ claims “can proceed, if at all, only if [state law] provides a cause of action based on a manufacturer’s failure to report adverse events to a regulator like the FDA, or to comply with post-approval requirements set by that regulator”
  • explaining that federal preemption is 13 affirmative defense
  • “To avoid implied preemption . . . claims must be based not on the FDCA, but on ‘traditional state tort law which . . . predated the federal enactments in question.” (quoting Buckman, 531 U.S. at 352–53)

Source: CourtListener parenthetical corpus (CC0).

Read full opinion on CourtListener

Cited by

7 cases in this archive cite this case.

Cites

22 cases in this archive are cited by this case; the 20 most cited are listed.

Other cases named Glover v. Bausch & Lomb, Inc.

2 other CourtListener records share this case name.

Sourced from CourtListener / Free Law Project (CC0).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.